Failure to Adequately Warn Patients About Known Risks The master complaint filed in MDL 3094 alleges that Novo Nordisk and Eli Lilly knew or should have known about the severe gastroparesis and vision loss risks associated with their GLP-1 medications but failed to provide adequate warnings on product labels, marketing materials, or prescribing information
Free Shipping: Orders over $300 ship free
Common flu-like manifestations include nausea (1540% incidence), fatigue, headaches, dizziness, and loss of appetite, particularly when starting or increasing doses
2 febbraio 2024;17(2):199 Allison KC, Chao AM, Bruzas MB, McCuen-Wurst C, Jones E, McAllister C, et al
Watch-out: No dietitian access
10.1056/NEJM199205143262003 16